Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
Long-term Follow-up Study to Assess Antibody Persistence in Children Previously Vaccinated With Four Doses of Pneumococcal Conjugate Vaccine in Primary Vaccination Study (105553) and Booster Vaccination Study (107046)
Sponsor: GlaxoSmithKline
This PHASE3 trial investigates Infections, Streptococcal and Streptococcus Pneumoniae Vaccines and is currently completed. GlaxoSmithKline leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2020 — Dec 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .